Barik Krishnendu, Arya Praffulla Kumar, Singh Ajay Kumar, Kumar Anil
Department of Bioinformatics, Central University of South Bihar, Gaya, 824236 India.
3 Biotech. 2023 Jan;13(1):9. doi: 10.1007/s13205-022-03423-9. Epub 2022 Dec 15.
has emerged as a sexually transmitted infection (STI) all over the world in the last three decades. It has been identified as a cause of male urethritis, and there is now evidence that it also causes cervicitis and pelvic inflammatory disease in women. However, the precise role of in diseases such as pelvic inflammatory disease, and infertility is unknown, and more research is required. It is a slow-growing organism, and with the advent of the nucleic acid amplification test (NAAT), more studies are being conducted and knowledge about the pathogenicity of this organism is being elucidated. The accumulation of data has improved our understanding of the pathogen and its role in disease transmission. Despite the widespread use of single-dose azithromycin in the sexual health field, is known to rapidly develop antibiotic resistance. As a result, the media frequently refer to this pathogen as the "new STI superbug." Despite their rarity, antibiotics available today have serious side effects. As the cure rates for first-line antimicrobials have decreased, it is now a challenge to determine the effective antimicrobial therapy. In this review, we summarise recent research and investigate potential therapeutic targets for combating this pathogen.
在过去三十年里，它已成为一种全球范围内的性传播感染（STI）。它已被确认为男性尿道炎的病因，现在有证据表明它也会导致女性宫颈炎和盆腔炎。然而，它在盆腔炎和不孕症等疾病中的确切作用尚不清楚，还需要更多研究。它是一种生长缓慢的微生物，随着核酸扩增检测（NAAT）的出现，正在进行更多研究，对这种微生物致病性的认识也在不断阐明。数据的积累增进了我们对病原体及其在疾病传播中作用的理解。尽管单剂量阿奇霉素在性健康领域广泛使用，但已知它会迅速产生抗生素耐药性。因此，媒体经常将这种病原体称为“新的性传播感染超级病菌”。尽管目前可用的抗生素罕见，但有严重的副作用。随着一线抗菌药物治愈率的下降，确定有效的抗菌治疗现在是一项挑战。在本综述中，我们总结了近期的研究，并探讨对抗这种病原体的潜在治疗靶点。
